==Long trade : CERS +9% (7/23)

•  7/17:  #83, vol. 820K

-=Cerus (CERS) reported earnings on Thur 2 Nov 2017 (a/h)

Cerus beats by $0.04, misses on revs 

• Reports Q3 (Sep) loss of $0.12 per share, $0.04 better than the Capital IQ Consensus of ($0.16); revenues rose 5.9% year/year to $10.8 mln vs the $11.95 mln Capital IQ Consensus.
• At September 30, 2017, the Company had cash, cash equivalents and short-term investments of $59.6 million compared to $71.6 million at December 31, 2016. 

=Cerus (CERS) reported earnings on Thur 3 Nov 2016 (a/h)

Cerus beats by $0.03, beats on revs; guides FY16 revs in-line  :

• Reports Q3 (Sep) loss of $0.14 per share, $0.03 better than the Capital IQ Consensus of ($0.17); revenues rose 27.5% year/year to $10.2 mln vs the $9.82 mln Capital IQ Consensus.
• Co issues in-line guidance for FY16, sees FY16 revs of $37-40 mln vs. $38.61 mln Capital IQ Consensus Estimate.
• "Beyond platelets and plasma, we are also moving forward with activities related to our red cell program, with plans to submit for European CE Mark approval and to initiate a U.S. Phase III trial."